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© 201? Japanese Society of Tropical Medicine Abstract: Dengue is one of the most important mosquito-borne viral illnesses. The first DHF outbreak was
reported from the Philippines in 1953. Initially it was endemic only in Southeast Asia and the Western Pacific
regions. After about 50 years from the first outbreak, it spread globally to almost every continent including North
and South America, Australia and Africa. The majority of cases during the 50s to 80s were children, but today
the disease affects both children and adults of all age groups. The disease is caused by dengue viruses that have
four serotypes: dengue 1, dengue 2, dengue 3 and dengue 4. Primary infection usually results in milder illness,
while more severe disease occurs in cases of repeated infection with different serotypes. In this paper clinical
manifestations and management of dengue/DHF/DSS are summarized.
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INTRODUCTION
The clinical presentations of dengue viral infections
range from asymptomatic to severe illness that may lead to
death if not properly managed. The symptomatic cases are
categorized as undifferentiated febrile illness (UF), dengue
fever (DF), dengue hemorrhagic fever (DHF), dengue shock
syndrome (DSS) and unusual dengue (UD) or expanded
dengue syndrome (EDS) [1].
￿ UF cannot be diagnosed clinically and the diagnosis is
based on serology or virology.
￿ DF is considered to be a mild disease because death is
rarely reported, but massive bleeding may be associated
with DF.
￿ DHF – clinical presentations during the febrile phase
are similar to those in DF. The distinct feature of DHF is
the increase in vascular permeability (plasma leakage)
that differentiates DHF from DF. The plasma leakage
is selective leakage into the pleural and peritoneal
cavities that results in pleural effusion and ascites.
￿ DSS – presentations are the same as those in DHF but
the plasma leakage is so severe that the patient develops
shock.
￿ UD – most of the unusual cases are DHF cases with
prolonged shock or DHF inpatients with co-morbidities
or DHF together with other infections [2].
The majority of the cases are UF and DF. DHF/DSS
accounts for about 10% of the symptomatic cases [3].
CASE DEFINITION OF SUSPECTED 
DENGUE INFECTION
In the first few days of dengue illness, most patients
present with acute febrile illness with non-specific signs and
symptoms: headache, malaise, nausea/vomiting, abdominal
pain and sometimes rash. Retro-orbital pain, myalgia and
arthralgia are found mostly in DF patients, but some DHF/
DSS may also have these symptoms. The most common
bleeding manifestations are petechiae and other symptoms
(epistaxis, gum bleeding, hematemesis, melena, hyper-
menorrhea, hemoglobinuria) which help in identifying early
suspected dengue but are often missed by doctors/nurses in
busy out-patient or primary care units. Tourniquet test is a
simple tool that helps in the early diagnosis of dengue infec-
tion.
The standard tourniquet test, the Winthrobe technique,
involves raising the blood pressure to midway between
systolic and diastolic pressure for five minutes. Then release
pressure and wait about one minute or until the circulation
comes back to normal. Read the result. The positive test is
≥ 10 petechiae/mm
3 (Figure 1). The Daisy technique for
tourniquet test is easier and can be used in children > five
years old and adults. In this technique, pressure is applied to
80 mmHg for five minutes and then released and the result
read as in the Winthrobe technique [2].
According to the WHO 2011 case definition [1], dengue
infection is suspected in a patient with high fever and two of
the following signs or symptoms:
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￿ Headache
￿ Retro-orbital pain
￿ Myalgia
￿ Arthralgia/ bone pain
￿ Rash
￿ Bleeding manifestations: petechiae, epistaxis, gum
bleeding, hematemesis, melena, or positive tourniquet
test.
￿ Leukopenia (WBC ≤ 5,000 cells/mm
3)
￿ Platelet count ≤ 150,000 cell/mm
3
￿ Hematocrit (Hct) rising 5–10%.
In Thailand, the case definition for dengue for surveil-
lance, control and early clinical diagnosis uses the follow-
ing two criteria: tourniquet test positive or petechiae +
leukopenia. The positive predictive value of this case
definition is 70–83% [3, 4].
CASE DEFINITION OF DHF
The modified WHO/SEARO 2011 criteria are as follows:
Major criteria: plasma leakage: elevation of Hct ≥ 20%,
detection of ascites, pleural effusion by physical examina-
tion, chest film (right lateral decubitus position) or ultra-
sound,
Minor criteria: 1. bleeding or positive tourniquet test.
2. Platelet counts ≤ 100,000 cells/mm
3.
Patients who have evidence of plasma leakage do not
necessarily have bleeding or positive tourniquet test and
their platelet count can be around 100,000 cells/mm
3.
DHF severity is divided into four grades according to
the severity:
￿ DHF grade I, DHF grade II – DHF
￿ DHF grade III and DHF grade IV – DSS
CLINICAL COURSE OF DHF
DHF clinical course (Figure 2) is divided into three
phases: febrile phase (2–7 days), critical or leakage phase
(24–48 hours), and convalescence phase (2–7 days). In the
febrile phase, only supportive and symptomatic treatment is
conducted. At the end of the febrile phase, plasma leakage
begins. More severe cases, i.e. those with moderate to severe
plasma leakage and without adequate oral intake, need
hospital admission and proper intravenous replacement.
Milder cases with minimal plasma leakage and adequate
oral intake may recover without treatment. It should be
noted that after the critical period, ascites and pleural
effusion will be reabsorbed back into the circulation 12–24
hours after leakage stops, i.e. 36–48 hours after shock or
60–72 hours after plasma leakage.
Management of patients [2, 3]
The management of patients with dengue infections
depends on the phase of illness, i.e. febrile phase, critical/
leakage phase and convalescence phase, as follows:
1. Febrile phase [2–4]: 
(Early diagnosis of dengue infection: )
Clinical sign:
￿ High fever with positive Tourniquet test + leukopenia
(WBC ≤ 5,000 cells/mm
3) – positive predictive value
70–83% [4, 5]
Rapid diagnostic test:
￿ NS1Ag test during the febrile phase (first five days of
fever): sensitivity 60–70%, specificity >99%
￿ PCR – good sensitivity and specificity but expensive
and not available in most places
￿ ELISA- IgM, IgG test – not suitable for early diagnosis
because the antibody significantly rises after day 5 of
fever
(Management)
￿ Reduction of high fever: paracetamol only, tepid sponge
￿ Promote oral feeding: soft diet, milk, fruit juice, oral
rehydration solution (ORS). Avoid IV fluid if there is
no vomiting and moderate/ severe dehydration
￿ Follow up CBC everyday
￿ Advise to come back to the hospital ASAP when there
is no clinical improvement despite a lack of fever,
severe abdominal pain/ vomiting, bleeding, restless/
irritable, drowsy, refusal to eat or drink (some patients
may be thirsty), urine not passed for 4–6 hours
2. Critical/ Leakage phase: 
(Early detection of plasma leakage/ shock:)
￿ Thrombocytopenia, i.e. platelet count ≤ 100,000 cells/
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mm
3, is the best indicator for plasma leakage: Platelet
count between 50,000 and 100,000 cells/mm
3 – begin-
ning of plasma leakage (about half of DF patients have
thrombocytopenia at this level), platelet count < 50,000
cells/mm
3 – DHF is most likely and usually indicates
that plasma leakage has occured, probably for 24 hours.
￿ Admit patients with thrombocytopenia and poor
appetite/ poor clinical conditions. Consider admitting
high risk patients: infants, obese patients, patients with
prolonged shock (grade IV), bleeding, encephalopathy,
underlying diseases, pregnancy.
￿ Detection of pleural effusion and ascites by physical
examination in the early leakage phase or even at the
time of shock is very difficult. Chest film – right lateral
decubitus technique, ultrasonogarphy or serum albumin
≤ 3.5 gm% are the alternative ways to detect plasma
leakage.
(Proper IV fluid management during the critical period:)
￿ Isotonic salt solution in the critical period, e.g. 5%
dextrose in normal saline solution (NSS), 5% Ringer
Acetate, 5% Ringer-Lactate. The 5% dextrose in NSS
is preferable because the severe cases needing admis-
sion are those with poor appetite, nausea/ vomiting and
abdominal pain.
￿ The total amount of fluid needed during the critical
period of 24–48 hours is estimated to be maintenance
+ 5% deficit (M+5%D), including oral and IV fluids.
In DSS patients the duration of IV fluid may be 24–36
hours and in non-shock DHF 48–60 hours.
￿ The rate of IV fluid should be adjusted according to
clinical vital signs (BP, pulse, respiratory rate, temper-
ature), hematocrit (Hct) and urine output (0.5 ml/kg/hr)
￿ The rate of IV fluid for shock patients (DHF grade III)
is shown in Figure 3. The IV fluid resuscitation for
DHF grade III is less than that recommended for other
kinds of shock, i.e. only 10 ml/kg/hr, not 20 ml/kg/hr
or over. A larger amount of IV fluid is needed for DHF
grade IV, but the rate should be reduced to 10 ml/kg/hr
as soon as the blood pressure is restored.
￿ The rate of IV fluid for non-shock patients (DHF grade
I and II) is shown in Figure 4. The administration
should begin at a slower rate if leakage is in the earlier
stage, i.e. platelet count is between 50,000 and 100,000
cells/mm
3. The rate of IV should be more rapid when
the leakage has continued for some time, i.e. platelet
count < 50,000 cells/mm
3.
￿ If the clinical response is not good (re-shock, unstable
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vital signs, inability to reduce the rate of IV fluid)
investigate and correct the following laboratory data:
A – Acidosis – blood gas (capillary or venous), if
present, check liver and renal functions. Correct
acidosis when blood pH is < 7.35 and HCO3 < 15
mEq/L.
B – Bleeding – Hct: if high, dextran is indicated,
if low or not rising, consider blood transfusion
and consider giving vitamin K1 intravenously.
C – iCa and other electrolytes: Na, K. Give caglu-
conate 1 ml/kg/dose diluted twice with IV fluid
and IV push slowly. Maximum dose is 10 ml/dose.
S – Blood sugar
￿ Colloidal solution: only plasma expander that has an
osmolarity higher than that of plasma is recommended,
e.g. 10% Dextran-40 in NSS. Bolus dose of 10 ml/kg/hr
in children or 500 ml/hr in adults is recommended, and
this will usually bring the Hct down to 10 points in cases
with signs of fluid overload or persistently high Hct.
￿ In cases with significant bleeding, i.e. > 6–8 ml/kg
ideal body weight in children or 300 ml in adult, blood
transfusion is recommended as soon as possible. The
amount to transfuse is equal to the estimated amount.
If it is impossible to estimate (concealed internal
bleeding), transfuse 10 ml/kg of fresh whole blood
(FWB) or 5 ml/kg of packed red cells (PRC) in
children to raise Hct by 5 points. In adults, transfuse 1
unit of FWB or PRC.
￿ Platelets are indicated in cases with significant
bleeding. If the patient already has signs of fluid
overload, however, do not give platelets because this
will cause fluid overload (possibly acute pulmonary
edema). Platelet transfusion is only adjunct therapy,
not specific treatment. There is no platelet prophylaxis
in children, no matter how low the platelet count.
Clinicians may consider prophylactic platelet transfu-
sion in adults with underlying hypertension or heart
disease and a platelet count < 10,000 cells/mm
3.
￿ Plasma has almost no role in the management of acute
DHF in the critical phase.
￿ Steroid has no role in the management of DSS.
￿ At the children’s hospital, Bangkok, DHF/DSS patients
were treated with NSS (100%), Dextran-40 (20–25%),
blood transfusion (10–15%) and platelet transfusion
(0.4%) [3].
3. Convalescence phase:
￿ Stop IV fluid when there are signs of recovery: conva-
lescence rash, itching, increase in appetite or > 30 hours
after shock and > 60 hours after plasma leakage. Sinus
bradycardia may be observed in some patients.
￿ Patients who have massive ascites and pleural effusion
may need diuretic during this period of reabsorption of
extravasated plasma into the circulation.
￿ Some patients may not regain their appetite in this
period. This may be due to diuresis and loss of
potassium in the urine. Potassium supplement may be
necessary in this phase. Fruit (bananas, oranges) and
fruit juice are rich in potassium and are preferred by
most patients.
￿ In adults, the convalescence period may extend for
2–4 weeks with fatigue.
4. Management of volume overload [2]
The most common complication in DHF/DSS manage-
ment is fluid overload, which may lead to heart failure, acute
pulmonary edema or even death if not managed properly
and timely.
Steps in the management of fluid overload:
1) Early detection of signs and symptoms of fluid over-
load.
Early signs of fluid overload: puffy eyelids, tachypnea,
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distended abdomen with abdominal discomfort
Late signs of fluid overload = indication for diuretic
(furosemide 1 mg/kg/dose)* : Cough, respiratory distress
(dyspnea/ orthopnea), very tense abdomen, wide pulse
pressure (some may have narrowing of pulse pressure),
strong and bounding pulse, hypertension (reabsorption
phase), abnormal lung signs (crepitation, rhonchi,
wheezing). Urinary catheter should be inserted in
every patient with late signs of fluid overload.
2) Know the status of the patient: time after shock or time
after plasma leakage. If the patients are still in the
leakage phase, dextran bolus is recommended 15–30
minutes before administer furosemide.
3) Status of the patient at that time: shock or non-shock.
If the patients are in shock state, dextran bolus is
recommended for 15–30 minutes before administer
furosemide.
4)  Assessment and correct associated complications:
bleeding, electrolyte/metabolic/acid-base disturbance,
liver/renal failure?
* Clinicians are urged to measure the vital signs four
times at 15-minute intervals after furosemide admin-
istration because furosemide acts for less than 1 hour.
5. Management of DHF with encephalopathy [2]:
Most cases of encephalopathy are observed in DHF
patients during or after the critical phase, but it may occur
early in the febrile phase. Few cases are found among
DF patients. The presentations include behavior change
(aggression, violence, vulgar language), consciousness
change (irritation, agitation, confusion, hallucinations, coma)
and convulsion.
More than half of DHF patients who present with
encephalopathy are cases of prolonged shock and liver/
renal failure. The other common causes are hyponatremia,
hypoglycemia and hypocalcemia. Intracranial bleeding,
although quite rare, is usually found in DSS patients with
prolonged shock and multi-organ failure and occurs very
late, i.e. > 3 days after shock.
Management of dengue encephalopathy is generally
the same as that of hepatic encephalopathy, as follows:
1) Maintain adequate airway oxygenation with oxygen
therapy. Intubation may be necessary for patients who
are in respiratory failure or semi-coma/ coma.
2) Prevent/ reduce ICP by the following measures:
Give minimal IV fluid to maintain adequate intra-
vascular volume, ideally the total IV fluid should
not exceed 80% maintenance
Switch to colloidal solution earlier if Hct continues
to rise or a large volume of IV is needed in cases
with severe plasma leakage.
Administer diuretic if indicated in cases with
signs and symptoms of fluid overload.
Consider steroids to reduce ICP. Dexamethazone
0.5 mg/kg/day IV every 6–8 hours is recom-
mended.
Hyperventilation?
3) Decrease ammonia production:
Give lactulose 5–10 ml every 6 hours for induc-
tion of osmotic diarrhea.
Local antibiotics to eliminate bowel flora. This is
not necessary if systemic antibiotics are given.
4) Maintain blood sugar level > 60 mg%. Recommend
glucose infusion rate between 4–6 mg/kg/hour.
5) Correct acid-base and electrolyte balance, e.g. correct
hypo/hypernatremia, hypo/hyperkalemia, hypocalcemia
and acidosis.
6) Vitamin K1 IV administration: 3 mg for < 1 year old,
5 mg for < 5 years old and 10 mg for > 5 years old and
adults.
7)  Anti-convulsants should be given for control of
seizures; phenobarbital, dilantin and diazepam IV as
indicated.
8) Transfuse blood, preferably fresh packed red cells as
indicated. Other blood components such as platelets
and fresh frozen plasma should not be given because
the fluid overload may cause increased ICP.
9) Empiric antibiotic therapy may be indicated if sus-
pected superimposed bacterial infections occur.
10) H2-blockers or proton pump inhibitor may be given to
alleviate gastro-intestinal bleeding.
11) Avoid unnecessary drugs because most drugs have to
be metabolized by the liver.
12)  Consider plasmapheresis or hemodialysis or renal
replacement therapy in cases of clinical deterioration.
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